CliffBio
small molecule

JANUMET

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

Loss of exclusivityJanuary 2029latest FDA-listed patent expiry
CompanyMERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC

Drug detail

Brand nameJANUMET
Active ingredientMETFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE
Strength500MG;EQ 50MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2007
Marketing statusRX

Listed patents

PatentExpiresType
8414921*PEDJanuary 2029—
8414921July 2028product
7326708*PEDMay 2027—
7326708November 2026substance, product

More from MERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

JANUMET patent cliff — loss of exclusivity January 2029 | CliffBio